Endothelial nitric oxide synthase (eNOS) is responsible for maintaining systemic blood pressure, vascular remodeling and angiogenesis. In addition to producing NO, eNOS can also generate superoxide (O-2(-center dot)) in the absence of the cofactor tetrahydrobiopterin (BH4). Previous studies have shown that bovine eNOS serine 1179 (Serine 1177/human) phosphorylation critically modulates NO synthesis. However, the effect of serine 1179 phosphorylation on eNOS superoxide generation is unknown. Here, we used the phosphomimetic form of eNOS (S1179D) to determine the effect of S1179 phosphorylation on superoxide generating activity, and its sensitivity to regulation by BH4, Ca2+, and calmodulin (CAM). S1179D eNOS exhibited significantly increased superoxide generating activity and NADPH consumption compared to wild-type eNOS (WT eNOS). The superoxide generating activities of S1179D eNOS and WT eNOS did not differ significantly in their sensitivity to regulation by either Ca2+ or CaM. The sensitivity of the superoxide generating activity of S1179D eNOS to inhibition by BH4 was significantly reduced compared to WT eNOS. In eNOS-overexpressing 293 cells, BH4 depletion with 10mM DAHP for 48 hours followed by 50ng/ml VEGF for 30 min to phosphorylate eNOS S1179 increased ROS accumulation compared to DAHP-only treated cells. Meanwhile, MTT assay indicated that overexpression of eNOS in HEK293 cells decreased cellular viability compared to control cells at BH4 depletion condition (P<0.01). VEGF-mediated Serine 1179 phosphorylation further decreased the cellular viability in eNOS-overexpressing 293 cells (P<0.01). Our data demonstrate that eNOS serine 1179 phosphorylation, in addition to enhancing NO production, also profoundly affects superoxide generation: S1179 phosphorylation increases superoxide production while decreasing sensitivity to the inhibitory effect of BH4 on this activity.
机构:
Harbor UCLA Med Ctr, Div Neonatol, Los Angeles Biomed Res Inst, Torrance, CA 90502 USAHarbor UCLA Med Ctr, Div Neonatol, Los Angeles Biomed Res Inst, Torrance, CA 90502 USA
John, Theresa A.
Ibe, Basil O.
论文数: 0引用数: 0
h-index: 0
机构:
Harbor UCLA Med Ctr, Div Neonatol, Los Angeles Biomed Res Inst, Torrance, CA 90502 USAHarbor UCLA Med Ctr, Div Neonatol, Los Angeles Biomed Res Inst, Torrance, CA 90502 USA
Ibe, Basil O.
Raj, J. Usha
论文数: 0引用数: 0
h-index: 0
机构:
Harbor UCLA Med Ctr, Div Neonatol, Los Angeles Biomed Res Inst, Torrance, CA 90502 USAHarbor UCLA Med Ctr, Div Neonatol, Los Angeles Biomed Res Inst, Torrance, CA 90502 USA
Raj, J. Usha
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY,
2008,
35
(02):
: 148
-
158
机构:
Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USAMed Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA
Kondrikov, Dmitry
Fonseca, Fabio V.
论文数: 0引用数: 0
h-index: 0
机构:
Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USAMed Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA
Fonseca, Fabio V.
Elms, Shawn
论文数: 0引用数: 0
h-index: 0
机构:
Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USAMed Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA
Elms, Shawn
Fulton, David
论文数: 0引用数: 0
h-index: 0
机构:
Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA
Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USAMed Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA
Fulton, David
Black, Steven M.
论文数: 0引用数: 0
h-index: 0
机构:
Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USAMed Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA
机构:
Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA
Med Coll Georgia, Dept Med, Augusta, GA 30912 USA
Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA
Med Coll Georgia, Ctr Biotechnol & Genom Med, Augusta, GA 30912 USAMed Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA